§ 37:1251 — Disclosure of prescription drug price information

§1251. Disclosure of prescription drug price information
A.(1) The Louisiana Board of Pharmacy shall develop a website to contain
prescription drug price information to be made available to Louisiana prescribers on the
board's website with a dedicated link that is prominently displayed on the board's home page,
or by a separate easily identifiable internet address.
(2) The website shall include, at a minimum, the following data elements, separated
by therapeutic category:
(a) Name of the product.
(b) Whether the drug is a brand name or a generic.
(c) Drug strength.
(d) Per-unit wholesale acquisition cost of the drug.
(e) Any disclaimers deemed appropriate by the board.
(3) When a pharmaceutical marketer engages in any form of prescription drug
marketing directly to a prescriber, his designee, or any member of his staff, the marketer may
disclose the website's internet address and inform the prescriber that he may access the
website to obtain information on the cost of prescription drugs. The provisions of this
Section shall only apply to pharmaceutical marketing engaged in by a pharmaceutical
marketer and a prescriber licensed by the state of Louisiana, his designee, or any member of
his staff, while physically present in the state of Louisiana.
(4) The board shall have the authority to enter into a contract for the administration
of the board's responsibilities pursuant to this Section.
(5) Each health profession licensing board that regulates individuals with prescriptive
authority in Louisiana shall advise the licensees of the board at least once annually of the
opportunity to access this website.
B. For purposes of this Section:
(1) "Pharmaceutical marketer" means a person who, while employed by or under
contract to represent a pharmaceutical manufacturing company engages in marketing
activities of prescription drugs.
(2) "Prescriber" means a physician or any other person authorized to prescribe
prescription drugs or any other person on their staff who receives prescription drug marketing
materials.
(3) "Prescription drug" means a pharmaceutical drug that legally requires a
prescription to be dispensed.
(4) "Prescription drug marketing" means in-person meetings, mailings, telephonic
conversations, video conferencing, and electronic mail activities with prescribers.
(5) "Wholesale acquisition cost" means, with respect to a pharmaceutical drug or
biological product, the manufacturer's list price for the pharmaceutical drug or biological
product to wholesalers or direct purchasers in the United States for the most recent month
for which the information is available, as reported in wholesale price guides or other
publications of pharmaceutical drug or biological product pricing data, not including prompt
pay or other discounts, rebates, or reductions in price.
C.(1) Implementation of this Section shall be contingent upon the Louisiana Board
of Pharmacy's obtaining grant funds from private entities for the development,
implementation, operation, and continued maintenance of the drug pricing disclosure
website.
(2) The board shall actively seek grant funding to implement the provisions of this
Section. Within ten months of successful receipt of grant funds sufficient in amount to
implement the provisions of this Section, the board shall make the drug pricing disclosure
website available to prescribers.
D. The provisions of this Section shall not apply to veterinarians or pharmaceutical
marketers who engage in any form of prescription drug marketing directly to a prescriber,
his designee, or any member of his staff regarding prescription drugs manufactured
exclusively for nonhuman consumption.

Legislative History

Acts 2017, No. 236, §1, eff. June 14, 2017; Acts 2018, No. 219, §1.